Richard Williams

Richard brings over a decade of global clinical strategy and drug development experience in the biopharmaceutical industry to Kinnate. Prior to joining our team, he was Chief Medical Officer and Global Head of Oncology Programs at WuXi NextCODE where he was responsible for leading the clinical development of large-scale genomics and target biomarker discovery programs. Prior to WuXi NextCODE, he was with cancer detection company GRAIL as Group Medical Director and Program Lead of the Circulating Cell-Free Genome Atlas (CCGA), the largest-ever prospective study of circulating nucleic acids in cancer. He also guided the development of early clinical oncology assets as Head of Early Development Oncology Group and Early Development Leader at Amgen. While Senior Medical Director at Puma Biotechnology, Richard led the Phase 2 and Phase 3 trials in metastatic breast cancer and lung cancer for the development of the targeted cancer therapeutic Nerlynx® (neratinib). He was also a clinical hematology and oncology fellow, and later an NIH-funded faculty member at St. Jude’s Children’s Research Hospital where he focused on translational biology and therapeutics studies within the molecular oncology and hematological malignancies programs. Richard has co-authored 60 publications in high impact clinical, translational & basic research journals including NEJM, Nature and Cancer Cell, and is the coinventor on 2 patents. He holds an MBBS and PhD as well as a BMedSc from the University of Queensland, Australia.